SPI
18.219,49
PKT
+34,44
PKT
+0,19
%
Werbung
Analysen zu SPI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 08.05.12 | Nestlé overweight | Morgan Stanley | |
| 08.05.12 | Swiss Life buy | Sarasin Research | |
| 08.05.12 | Adecco SA buy | Sarasin Research | |
| 08.05.12 | Lonza kaufen | Die Actien-Börse | |
| 08.05.12 | Swiss Life hold | Société Générale Group S.A. (SG) | |
| 08.05.12 | StarragTornos hold | Vontobel Research | |
| 08.05.12 | Swiss Life buy | Vontobel Research | |
| 08.05.12 | Adecco SA buy | Vontobel Research | |
| 08.05.12 | Cicor Technologies buy | Vontobel Research | |
| 07.05.12 | Swiss Re underperform | RBC Capital Markets | |
| 07.05.12 | Swiss Re kaufen | Hamburger Sparkasse AG (Haspa) | |
| 07.05.12 | Lonza hold | Vontobel Research | |
| 07.05.12 | Swiss Re buy | Vontobel Research | |
| 07.05.12 | Holcim hold | Société Générale Group S.A. (SG) | |
| 07.05.12 | ARYZTA buy | Vontobel Research | |
| 07.05.12 | StarragTornos hold | Vontobel Research | |
| 07.05.12 | Roche buy | Vontobel Research | |
| 04.05.12 | Swiss Re add | Commerzbank Corp. & Markets | |
| 04.05.12 | UBS buy | Nomura | |
| 04.05.12 | Novartis neutral | Banc of America Securities-Merrill Lynch | |
| 04.05.12 | Adecco SA outperform | Exane-BNP Paribas SA | |
| 04.05.12 | Clariant neutral | Exane-BNP Paribas SA | |
| 04.05.12 | Clariant neutral | HSBC | |
| 04.05.12 | Novartis buy | UBS AG | |
| 04.05.12 | Swiss Re buy | Sarasin Research | |
| 04.05.12 | Lonza neutral | Sarasin Research | |
| 04.05.12 | Clariant buy | Vontobel Research | |
| 04.05.12 | Lonza underperform | Cheuvreux SA | |
| 04.05.12 | Swiss Re underperform | Cheuvreux SA | |
| 04.05.12 | Holcim hold | Vontobel Research | |
| 04.05.12 | StarragTornos hold | Vontobel Research | |
| 04.05.12 | Clariant sell | Société Générale Group S.A. (SG) | |
| 04.05.12 | Lonza hold | Vontobel Research | |
| 04.05.12 | Swiss Re buy | Vontobel Research | |
| 03.05.12 | Clariant buy | Sarasin Research | |
| 03.05.12 | Allreal neutral | Sarasin Research | |
| 03.05.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 07.05.12 | UBS outperform | RBC Capital Markets | |
| 03.05.12 | Swisscom outperform | Exane-BNP Paribas SA | |
| 03.05.12 | UBS hold | Deutsche Bank AG |